HOME >> BIOLOGY >> NEWS
Host response to anthrax lethal toxin suggests some current treatment strategies are inappropriate

Anthrax, a disease previously primarily relevant to the livestock-management community recently became a wordwide bioterrorism concern. However, human anthrax infection is primarily a result of direct or indirect contact with infected animals or exposure to contaminated animal products.

Bacillus anthracis, the causative agent of anthrax, is believed to induce disease and death in humans in an endotoxic shocklike manner. A comprehensive study of the effects of anthrax lethal toxin in mice by Stephen Leppla and colleagues at the National Institutes of Health demonstrated that toxin-induced death does not result from septic shock mediated by cytokine release as previously thought, but via hypoxia-induced liver failure. The study strongly suggests that the therapies developed for the treatment of cytokine-mediated septic shock will not be appropriate for the treatment of anthrax.

In an accompanying commentary, Alice Prince from Columbia University College of Physicians and Surgeons in New York states that "this analysis of the pathological effects of the B. anthracis lethal toxin should help focus future studies of optimal therapy for patients exposed to this organism. These results make clear that anthrax patients exhibit a unique pathophysiology and should not be considered to have generic shock analogous to Gram-negative sepsis". Prince continues "exactly how the lethal factor produces such profound tissue hypoxia, what metabolic processes are affected in the liver and elsewhere, and how these effects may be blocked will require further studies".


'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
2-Sep-2003


Page: 1

Related biology news :

1. Columbia research to examine gene influence on severity of peridontal disease, therapy response
2. Protective gene may enhance vaccine responses
3. Activated signaling pathway may predict lung cancer patients response to gefitinib
4. Duke study disputes idea that trees can relocate quickly in response to climate change
5. Researchers develop better understanding of immune response to viral infection
6. Molecular motor shuttles key protein in response to light
7. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys
8. Genetic basis for individual variations in the response to stress
9. Drunken worms reveal a genetic basis of alcohol response
10. Researchers identify genetic markers to predict response to chemotherapy for colorectal cancer
11. With fat, women have a more visceral response

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/9/2019)... ... ... With a demand in healthcare to lower unneeded emergency room visits and ... (UCC) in the coming years, according to a new report on the industry by ... , is a detailed look at the current state of these healthcare outlets, including ...
(Date:8/6/2019)... ... 2019 , ... VetStem Biopharma has long been ... experience. In November it spun out a human regenerative medicine subsidiary, ... of the first cGMP cell manufacturing facilities in California , VetStem signed ...
(Date:8/6/2019)... ... August 05, 2019 , ... ... announce its attendance at the Microscopy & Microanalysis 2019 Meeting ( M&M 2019 ... Oregon Convention Center. , The Microscopy & Microanalysis Meeting, organized by the Microscopy ...
Breaking Biology News(10 mins):
(Date:8/6/2019)... ... 2019 , ... Shoreline Biome, a microbiome research ... has announced partnerships with six international distributors. , The distributors will sell ... Australia, Benelux, Indonesia, Korea, Malaysia, Myanmar, New Zealand, Singapore, the United Kingdom, and ...
(Date:7/26/2019)... ... July 25, 2019 , ... LeadingBiotech , ... dialogue, today announces its Boston BD conference to be held on ... Biotech Week Boston , the event provides an opportunity for attendees to leverage ...
(Date:7/17/2019)... ... July 16, 2019 , ... ... and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for ... will have dedicated manufacturing space at the new, state-of-the-art commercial manufacturing center ...
(Date:7/2/2019)... ... , ... Leading Regenerative Veterinary Medicine company, VetStem Biopharma , was recently ... film focuses on regenerative veterinary medicine as a means of improving the quality of ... in the Brentwood and Pacific Palisades International Film Festival in Los Angeles, California where ...
Breaking Biology Technology:
Cached News: